terbutaline sulphate.txt CLINICAL USE Beta2–adrenoceptor agonist: Reversible airways obstruction DOSE IN NORMAL RENAL FUNCTION Oral: 2.5–5 mg 3 times daily SC/IM/IV: 250–500 micrograms up to 4 times daily IV infusion : 90–300 micrograms/hour Turbohaler: 500 micrograms (1 inhalation) up to 4 times daily Nebulisation: 5–10 mg 2–4 times daily, or more frequently PHARMACOKINETICS Molecular weight                           : 548.6 %Protein binding                           : 15–25 %Excreted unchanged in urine     : 55–60 Volume of distribution (L/kg)       : 0.9–1.5 half-life – normal/ESRD (hrs)      : 16–20/– DOSE IN RENAL IMPAIRMENT GFR (mL/MIN) 20 to 50     : 50% of normal parenteral dose. Other routes Dose as in normal renal function 10 to 20     : 50% of normal parenteral dose. Other routes. Dose as in normal renal function <10           : Avoid parenteral dose. Other routes Dose as in normal renal function DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES CAPD                : Likely dialysability. Dose as in GFR <10 mL/min HD                     : Likely dialysability. Dose as in GFR <10 mL/min HDF/high flux   : Likely dialysability. Dose as in GFR <10 mL/min CAV/VVHD      : Likely dialysability. Dose as in GFR 10 to 20 mL/min IMPORTANT DRUG INTERACTIONS Potentially hazardous interactions with other drugs Effect may be diminished by beta-blockers Theophylline: increased risk of hypokalaemia ADMINISTRATION Reconstition – Route IV, SC, IM, oral, inhaled, nebulised Rate of Administration 1.5–5 mcg/minute Comments For IV infusion , add 1.5–2.5 mg to 500 mL glucose 5% or sodium chloride 0.9% (3–5 micrograms/mL) Tags: post-by-auto-php Continue Reading Previous Previous post: sodium valproate.txt Related News streptomycin.txt tolterodine tartrate.txt